Intracerebral Hemorrhage (ICH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Intracerebral Hemorrhage (ICH) Market Outlook
Thelansis’s “Intracerebral Hemorrhage
(ICH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Intracerebral Hemorrhage (ICH)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Intracerebral
Hemorrhage (ICH) Overview
Intracerebral
hemorrhage (ICH), a subtype of stroke, is a severe condition characterized by
the formation of a hematoma within the brain parenchyma, sometimes extending
into the ventricles. Accounting for 10-15% of all strokes, non-traumatic ICH is
linked with significant morbidity and mortality. Risk factors for ICH encompass
chronic hypertension, amyloid angiopathy, anticoagulant medication use, and
vascular malformations. Seizures often manifest as part of the initial symptoms
of ICH, though in some instances, they may present as a delayed complication
occurring approximately two hours post-hemorrhage. The diagnostic cornerstone
for ICH remains a non-contrast CT scan of the head due to its accessibility and
rapidity. Additionally, MR angiography and MR venography can identify vascular
abnormalities such as arteriovenous malformations and cavernomas. For patients
on vitamin K antagonists, guidelines recommend the management of spontaneous
ICH by correcting coagulopathy, aiming for an INR < 1.4. Correction methods
may include the administration of fresh frozen plasma (FFP), vitamin K,
prothrombin complex concentrates, and recently developed recombinant activated
factor VIIa.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment